SCHEMBL3115397

SCHEMBL3115397

Cc1nc(Cl)c(I)c(=O)n1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
MAPK1 P28482 1/20 0.50
HPGD P15428 5/20 0.49
TNF P01375 1/20 0.49
KDM4E B2RXH2 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
HSD17B10 Q99714 1/20 0.47
RAB9A P51151 2/20 0.46
GALR3 O60755 1/20 0.46
NR2F2 P24468 1/20 0.46
MAPT P10636 1/20 0.45
LMNA P02545 3/20 0.44
RECQL P46063 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PDE1A P54750 1/20 0.44
PDE1B Q01064 1/20 0.44
PDE1C Q14123 1/20 0.44
HDAC1 Q13547 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3108406 0.73 CFTR (0.55) ALDH1A1MAPK1HPGDTNFKDM4E
SCHEMBL14472561 0.73 ALDH1A1 (0.50) ALDH1A1MAPK1HPGDTNFKDM4E
SCHEMBL31196722 0.72 SMN1; SMN2 (0.70) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10
SCHEMBL3524860 0.72 CYP2C9 (0.50) ALDH1A1MAPK1HPGDTNFKDM4E
SCHEMBL1882530 0.71 SMN1; SMN2 (0.62) ALDH1A1HPGDTNFKDM4ESMN1; SMN2
SCHEMBL17066148 0.71 ALDH1A1 (0.55) ALDH1A1MAPK1HPGDTNFKDM4E
SCHEMBL28738377 0.71 CASR (0.55) ALDH1A1MAPK1HPGDKDM4ESMN1; SMN2
SCHEMBL13678559 0.70 ALDH1A1 (0.50) ALDH1A1MAPK1KDM4ESMN1; SMN2MAPT
SCHEMBL13167694 0.70 MAPK14 (0.49) ALDH1A1MAPK1HPGDTNFKDM4E
SCHEMBL5863348 0.69 KDM4E (0.81) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179127-A1 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2010-07-15 US disclosed
US-20100179127-A1 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2010-07-15 US disclosed
US-20100179127-A1 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2010-07-15 US disclosed
EP-1896428-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS Novartis AG (CH) 2008-03-12 EP disclosed
WO-2006136442-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS NOVARTIS AG (CH) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179127-A1 PYRIMIDINE DERIVATIVES DPYD, NUDT1, HPRT1 ALDH1A1 1213/4885MAPK1 2161/4885HPGD 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.